Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

ABSTRACT: Alemtuzumab is a humanized monoclonal antibody therapy that has recently been approved in over 30 countries for patients with active relapsing-remitting multiple sclerosis. It acts by targeting CD52, an antigen primarily expressed on T and B lymphocytes, resulting in their depletion and subsequent repopulation. The alemtuzumab clinical development program used an active comparator, subcutaneous interferon beta-1a, to show that alemtuzumab is a highly efficacious disease-modifying therapy, with benefits on relapses, disability outcomes, and freedom from clinical disease and magnetic resonance imaging activity. The safety profile was consistent across studies and no new safety signals have emerged during follow-up in the extension study. Infusion-associated reactions are common with alemtuzu

SUBMITTER: Havrdova E 

PROVIDER: S-EPMC4286943 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature